ACRIVON THERAPEUTICS
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal contexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.
ACRIVON THERAPEUTICS
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.acrivon.com
Total Employee:
51+
Status:
Active
Total Funding:
245.5 M USD
Technology used in webpage:
CrUX Top 50m Bamboo HR
Similar Organizations
2seventy bio
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
Biomea Fusion
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Checkpoint Therapeutics
Checkpoint Therapeutics is a clinical-stage, immuno-oncology biopharmaceutical company.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Alumis
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hummingbird Bioscience
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Leo Cancer Care
Leo Cancer Care constantly seeking to optimise and improve.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Board_member
2021-05-01
Board_member
Current Employees Featured
Eric Devroe SVP, Business Operations @ Acrivon Therapeutics
SVP, Business Operations
2020-10-01
Jean-Marie Cuillerot Chief Medical Officer @ Acrivon Therapeutics
Chief Medical Officer
2024-01-01
Kristina Masson Co-Founder, Co-President, SVP of Global Operations, & Site Head of subsidiary @ Acrivon Therapeutics
Co-Founder, Co-President, SVP of Global Operations, & Site Head of subsidiary
Peter Blume-Jensen President & CEO @ Acrivon Therapeutics
President & CEO
2018-04-01
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Acrivon Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Acrivon Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Acrivon Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Acrivon Therapeutics
Paradigm BioCapital Advisors
Paradigm BioCapital Advisors investment in Post-IPO Equity - Acrivon Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Post-IPO Equity - Acrivon Therapeutics
Marshall Wace
Marshall Wace investment in Series B - Acrivon Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Series B - Acrivon Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series B - Acrivon Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Acrivon Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-03 | Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.acrivon.com Semrush global rank: 5.03 M Semrush visits lastest month: 1.62 K
Unable to get host informations!!!
More informations about "Acrivon Therapeutics"
About - Acrivon
The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will …See details»
Acrivon Therapeutics - Crunchbase Company Profile
Additionally, Acrivon Therapeutics announced a $130 million private placement financing, which provides substantial capital for the company's operations and …See details»
People - Acrivon
Acrivon’s team is a rare blend of leading scientific pioneers and highly accomplished executives. The team is located at two Centers of Excellence in Boston and Lund/Copenhagen in …See details»
Acrivon Company Profile - Office Locations, Competitors ... - Craft
Aug 27, 2024 Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision …See details»
Acrivon - Org Chart, Teams, Culture & Jobs - The Org
View Acrivon's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Acrivon - Medicon Village
Acrivon is a clinical stage biotech company focused on developing and providing precision medicine solutions in oncology using our proprietary proteomics platform. The platform allows …See details»
Acrivon Therapeutics - Company Profile - Tracxn
Feb 2, 2025 Acrivon Therapeutics - Limited information available. Public Company. Raised a total funding of $116M over 2 rounds from 7 investors. Founded by Peter Blume-Jensen and …See details»
Acrivon Therapeutics - Funding, Financials, Valuation & Investors
Acrivon Therapeutics is registered under the ticker NASDAQ:ACRV . Their stock opened with $12.50 in its Nov 15, 2022 IPO. Stock Symbol NASDAQ:ACRV ; Valuation at IPO $260.7M; …See details»
Acrivon Therapeutics - Contacts, Employees, Board Members, …
Acrivon Therapeutics has 4 current employee profiles, including SVP, Business Operations Eric Devroe. Acrivon Therapeutics has 2 board members and advisors, including Sharon Shacham …See details»
Acrivon Therapeutics to Present Data Demonstrating …
Oct 17, 2024 Acrivon scientists to present data at two key scientific conferences demonstrating AP3’s proprietary and actionable machine learning-driven capabilities for drug discovery and clinical ...See details»
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana ...
Feb 8, 2024 Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to …See details»
Acrivon Therapeutics Announces FDA has Granted Breakthrough …
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of …See details»
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B ...
Nov 11, 2021 WATERTOWN, Massachusetts, November 11, 2021 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era …See details»
Acrivon Therapeutics to Present Data at AACR Annual Meeting ...
Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor …See details»
Contact - Acrivon
Acrivon Therapeutics acts to shut these false addresses and websites down whenever the company is made aware of them. Acrivon Therapeutics values every individual seeking to join …See details»
Acrivon Therapeutics (ACRV) Earnings Date and Reports 2025
5 days ago Acrivon Therapeutics (NASDAQ:ACRV) has a recorded net income of -$60.39 million. ACRV has generated -$2.70 earnings per share over the last four quarters. What is …See details»
Acrivon Therapeutics Announces FDA has Granted Breakthrough …
WATERTOWN, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine …See details»
Clinical Trials - Acrivon
Clinical Trials. Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators in accordance with good clinical …See details»
Acrivon Therapeutics:FDA Grants Breakthrough Device ... - Markets …
6 days ago (RTTNews) - Acrivon Therapeutics, Inc. (ACRV), Wednesday, announced that the FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for …See details»
Pipeline - Acrivon
Acrivon Pipeline. Acrivon’s Lead Program ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, potent selective inhibitor of the DNA Damage Response …See details»